Clinical Trials Using Vorinostat

Clinical trials are research studies that involve people. The clinical trials on this list are studying Vorinostat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-16 of 16
  • Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia

    This phase I / II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and combination chemotherapy in treating infants (patients less than 1 year old) with newly diagnosed acute lymphoblastic leukemia. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as methotrexate, hydrocortisone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) with bortezomib and vorinostat may be a better treatment for acute lymphoblastic leukemia.
    Location: 11 locations

  • 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat

    This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
    Location: 9 locations

  • Epigenetic Reprogramming in Relapse / Refractory AML

    This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
    Location: 8 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 4 locations

  • Pembrolizumab and Vorinostat in Treating Patients with Advanced or Metastatic Renal Cell, Urothelial, or Prostate Carcinoma

    This phase I / Ib trial studies the side effects of pembrolizumab and vorinostat and how well they work in treating patients with renal cell, urothelial, or prostate carcinoma that has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and vorinostat may work better in treating patients with renal cell, urothelial, or prostate carcinoma.
    Location: 3 locations

  • SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides

    The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The study will compare the effects of cobomarsen to vorinostat, a drug that has been approved for the treatment of CTCL in the United States, Canada, and Australia. Participants will be randomly assigned to receive either weekly doses of cobomarsen or daily doses of vorinostat. Participants will continue on their assigned treatment as long as their disease does not get worse or as long as they do not have unacceptable side effects. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects. Participants assigned to receive vorinostat who experience progression of their disease during their participation in this study may have the option to be treated with cobomarsen in a separate clinical trial, if they meet the entry criteria for that study.
    Location: 5 locations

  • Pembrolizumab, Vorinostat, Temozolomide and Radiation Therapy in Treating Participants with Newly Diagnosed Glioblastoma

    This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab, temozolomide and radiation therapy in treating participants with newly diagnosed glioblastoma. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab, vorinostat and temozolomide with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Pembrolizumab and Vorinostat in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab block cancer growth in different ways by targeting certain cells. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and pembrolizumab together may work better in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma.
    Location: 2 locations

  • Pembrolizumab and Vorinostat in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This partially randomized phase I / II trial studies the side effects of pembrolizumab when given together with vorinostat and how well they work in treating patients with stage IV non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab together with vorinostat may kill more tumor cells.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Vorinostat and Temsirolimus with or without Radiation Therapy in Treating Younger Patients with Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma

    This phase I trial studies the side effects and best dose of temsirolimus when given together with vorinostat and with or without radiation therapy in treating younger patients with newly diagnosed or progressive diffuse intrinsic pontine glioma, a tumor that arises from the middle portion of the brain stem. Vorinostat and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving temsirolimus and vorinostat with or without radiation therapy may be a better treatment for younger patients with diffuse intrinsic pontine glioma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sorafenib Tosylate, Vorinostat, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate and vorinostat when given together with gemcitabine hydrochloride and radiation therapy in treating patients with pancreatic cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sorafenib tosylate, vorinostat, gemcitabine hydrochloride, and radiation therapy may be a better treatment for pancreatic cancer.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer

    This randomized phase II trial studies how well vorinostat and hydroxychloroquine work compared with regorafenib in treating patients with colorectal cancer that has spread to other places in the body and does not respond to treatment. Vorinostat and regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine may suppress the immune system in different ways and stop tumor cells from growing or kill them. It is not yet known whether vorinostat and hydroxychloroquine work better than regorafenib in treating patients with refractory metastatic colorectal cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well it works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Vorinostat and Iobenguane I 131 in Treating Patients With Resistant or Relapsed Neuroblastoma

    This phase I trial studies the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor cells.
    Location: 16 locations

  • Olaparib and High-Dose Chemotherapy in Treating Participants with Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

    This phase I trial studies the side effects and best dose of olaparib when given together with high-dose chemotherapy in treating participants with lymphomas that have come back or does not treatment and are undergoing stem cell transplant. Drugs used in chemotherapy, such as olaparib, vorinostat, gemcitabine, busulfan, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving olaparib and high-dose chemotherapy may work better in treating participants with relapsed / refractory lymphomas undergoing stem cell transplant.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment. It may also help determine which drugs fight urothelial cancer based on the characteristics of a tumor. Researchers want to test if this model can choose the best therapy for advanced urothelial cancer within 3 weeks and how tumors respond to the next best therapy. Objective: To test if the COXEN model can choose the best therapy for advanced urothelial cancer within 3 weeks. Eligibility: People ages 18 and older whose urothelial cancer has spread after at least 1 line of chemotherapy Design: Participants will be screened with medical history, physical exam, blood and urine tests, and tumor scans. Participants will provide a tumor sample from a previous surgery and a new biopsy. A needle will remove a small piece of tumor. Participants will repeat screening tests, plus have an EKG and scan. For the scan, they will get an injection of radioactive drug. They will lie in a machine that takes pictures. Participants will take the drugs assigned by the COXEN model. They will have visits every 2 3 weeks. These will include blood and urine tests. Participants will have tumor scans every 8 9 weeks. Participants may have another biopsy. Participants will take the drugs until they can t tolerate the side effects or their cancer worsens. They may be assigned to a second COXEN therapy. Participants will have a follow-up visit 4 5 weeks after their last drug dose. Participants will be contacted by phone every few months until death.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland